Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bupropion + trazodone is a combination of two oral antidepressant medications commonly co-prescribed for the treatment of major depressive disorder, particularly in cases with sleep disturbances or when monotherapy is insufficient. - **Bupropion** is a norepinephrine-dopamine reuptake inhibitor (NDRI) that increases levels of norepinephrine and dopamine in the brain, supporting energy, mood, and attention. - **Trazodone** is a serotonin antagonist and reuptake inhibitor (SARI) that increases serotonin activity and is often used for its sedating effects to improve sleep quality. The combination aims to modulate multiple neurotransmitter systems: bupropion provides activating effects, while trazodone offers sedative and anxiolytic properties. The combined use can improve overall mood and sleep in depression, but requires medical oversight due to the potential for drug interactions (e.g., increased risk of serotonin syndrome, QTc prolongation, neuroleptic malignant syndrome, and cardiovascular or hepatic adverse effects)[1][4]. These two drugs do not have a unique marketed brand as a fixed combination; they are prescribed as individual agents in combination therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupropion + trazodone.